Corbus Pharmaceuticals presented new data from the first Western study of its antibody-drug conjugate treatment for cancer.

Corbus Pharmaceuticals (CRBP) announced that data from its US and UK conducted first-in-human dose escalation clinical study of CRB-701 is ...

Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall ...

Corbus Pharmaceuticals (CRBP) stock drops 12% after mixed Phase 1 trial results for its lead cancer candidate. Read more here.

In a report released on February 11, Brian Abrahams from RBC Capital maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research ...

HC Wainwright reaffirmed their buy rating on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research ...